205  0 Kommentare Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

“We are delighted to welcome Chris Boshoff to our executive leadership team as he works to accelerate the delivery of the next generation of cancer breakthroughs to patients around the world,” said Dr. Albert Bourla, Chairman and CEO, Pfizer Inc. “About 1 in 3 people will be diagnosed with cancer during their lifetime in the United States, which means just about every family will be impacted by this dreaded disease. Chris is an exceptional physician-scientist with the vision and expertise to unleash the scale and strength of Pfizer’s ambition in cancer research.”

Previously, Dr. Boshoff oversaw clinical research and product development activities for Pfizer’s Oncology portfolio, including 24 approved innovative cancer medicines and biosimilars in more than 30 indications, as well as Pfizer’s industry-leading Rare Disease portfolio of innovative medicines spanning four therapeutic areas. Before assuming leadership roles in the biopharmaceutical industry, Dr. Boshoff served as Director of the University College London (UCL) Cancer Institute. Dr. Boshoff earned his medical degree from University of Pretoria in South Africa, a PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. In addition to his expanded role, Dr Boshoff is leading the integration planning for Seagen’s medicines and team.

Lesen Sie auch

Nach den Zahlen

Cresco Labs und Trulieve Cannabis im Fokus

heute 08:54

"Große Kursrückgänge voraus"

Diese (Meme)-Aktien befinden sich in der "Gefahrenzone", sagt ein Analyst

gestern 11:56

Kurs bricht ein

Schott Pharma: Trübe Aussichten führen zu drastischem Kurseinbruch

15.05.24, 17:33

Technische Analyse

Gewinne abgegeben! Wird die Aktie von Bayer jetzt verkauft?

15.05.24, 06:27

Mikael Dolsten, M.D., PhD, currently Chief Scientific Officer & President, Pfizer Worldwide Research, Development and Medical, will now expand his role to lead all discovery, early- and late-stage clinical development, for all non-oncology therapeutic areas as Chief Scientific Officer, President, Pfizer Research & Development. In addition to his current leadership of discovery and early-phase clinical development, he will lead an end-to-end model across all of Pfizer’s other therapeutic areas. These therapeutic areas include Vaccines, Inflammation and Immunology, Internal Medicine and Infectious Diseases as well as non-malignant hematology and rare neuromuscular diseases.

Diskutieren Sie über die enthaltenen Werte

Pfizer

Aktie

Beiträge: 2.460